GlassScriptPhysician profile
Waheed K Bajwa
NPI 1487607123
$2,456.19
in general payments reported to CMS, 2019-2025
14 companies · $760 in 2025
The $760 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $22.95 · 2022: $358 · 2023: $358 · 2024: $211 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.77 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,058.03 | 2019-2025 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $256.54 | 2019 | |
| Abbvie INC. | $232.69 | 2025 | |
| Neurocrine Biosciences, INC. | $232.20 | 2022-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $216.30 | 2023-2025 | Sunosi, Auvelity |
| Alkermes, INC. | $114.99 | 2019 | |
| Allergan, INC. | $108.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $83.25 | 2024-2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $34.29 | 2024-2025 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $32.91 | 2022 | |
| Vanda Pharmaceuticals INC. | $23.61 | 2025 | Fanapt |
| Lundbeck LLC | $22.95 | 2020 | |
| Noven Therapeutics, LLC | $20.23 | 2025 | Xelstrym |
| Janssen Scientific Affairs, LLC | $19.87 | 2023 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waheed Bajwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.